BPR1R024 is primarily investigated for its potential in cancer therapy. It functions as a selective inhibitor targeting specific kinases involved in tumor growth and proliferation. By blocking these kinases, it can disrupt signaling pathways that promote cancer cell survival, making it a promising candidate for treating various malignancies. Research is focused on its efficacy in preclinical models, particularly in cancers resistant to conventional treatments. Its application extends to combination therapies, where it may enhance the effectiveness of existing chemotherapeutic agents. Ongoing studies aim to optimize its pharmacokinetics and safety profile for potential clinical use.